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LAY ABSTRACT
Severe acute respiratory syndrome (SARS) and Middle 
East Respiratory Syndrome (MERS) are two previous vi-
ral infection outbreaks similar to the current COVID-19 
pandemic. Studies that have looked at long-term health 
problems in survivors of these two outbreaks report 
reduced lung function and reduced ability to exercise 
in some survivors up to 6 months after discharge from 
hospital. Mental health problems including stress, an-
xiety and depression were observed in up to one-third 
of survivors at 6 months and beyond. The quality of life 
was observed to be low even 12 months after discharge 
from the hospital. Rehabilitation clinicians and services 
should anticipate similar health problems in survivors of 
COVID-19, investigate them accordingly and plan suit-
able and timely treatments to enable best possible re-
covery and quality of life for them.
Objective: To determine long-term clinical outco-
mes in survivors of severe acute respiratory syn-
drome (SARS) and Middle East respiratory syndrome 
(MERS) coronavirus infections after hospitalization 
or intensive care unit admission.
Data sources: Ovid MEDLINE, EMBASE, CINAHL Plus, 
and PsycINFO were searched. 
Study selection: Original studies reporting clini-
cal outcomes of adult SARS and MERS survivors 3 
months after admission or 2 months after discharge 
were included. 
Data extraction: Studies were graded using the Ox-
ford Centre for Evidence-Based Medicine 2009 Level 
of Evidence Tool. Meta-analysis was used to derive 
pooled estimates for prevalence/severity of outco-
mes up to 6 months after hospital discharge, and 
beyond 6 months after discharge.
Data synthesis: Of 1,169 identified studies, 28 were 
included in the analysis. Pooled analysis revealed 
that common complications up to 6 months after 
discharge were: impaired diffusing capacity for car-
bon monoxide (prevalence 27%, 95% confidence in-
terval (CI) 15–45%); and reduced exercise capacity 
(mean 6-min walking distance 461 m, CI 450–473 
m). The prevalences of post-traumatic stress dis-
order (39%, 95% CI 31–47%), depression (33%, 
95% CI 20–50%) and anxiety (30%, 95% CI 10–61) 
beyond 6 months after discharge were considerable. 
Low scores on Short-Form 36 were identified beyond 
6 months after discharge.
Conclusion: Lung function abnormalities, psycho-
logical impairment and reduced exercise capacity 
were common in SARS and MERS survivors. Clinici-
ans should anticipate and investigate similar long-
term outcomes in COVID-19 survivors.
Key words: coronavirus infection; follow-up; follow-up stu-
dies; COVID-19; prevalence; lung function; exercise tole-
rance; post-traumatic stress disorder; depression; anxiety; 
fatigue; quality of life; SARS; MERS, ARDS. 
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Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and coronavi-
rus disease 2019 (COVID-19) are 3 major coronavirus 
(CoV) outbreaks that have occurred in the 21st century 
(1). SARS, caused by SARS-CoV, originated in China 
in 2002 and MERS, caused by MERS-CoV, originated 
in Saudi Arabia in 2012 (1). Like COVID-19, cau-
sed by SARS-CoV-2 (2), both of these diseases are 
members of the same virus family and result in viral 
pneumonia and may lead to acute respiratory distress 
syndrome (ARDS) (1, 3). 
Alongside acute challenges, the SARS and MERS 
outbreaks resulted in significant long-term clinical pro-
blems for survivors, with implications for rehabilitation 
services and healthcare utilization (4, 5). Whilst there 
are currently no long-term follow-up studies investiga-
ting COVID-19, these long-term outcomes have been 
documented in survivors of SARS and MERS. Les-
sons should be learned from these previous outbreaks 
and used to predict potential long-term (> 3 months) 
complications of COVID-19 in survivors. 
The aim of this review is to determine the long-
term clinical complications for survivors of SARS 
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and MERS after hospitalization and intensive care 
unit (ICU) admission. The findings of this review will 
inform rehabilitation clinicians in anticipating similar 
problems in COVID-19 survivors and planning inter-
ventions and services for timely input and restoration 
of function in these individuals.
METHODS
The protocol for this systematic review and meta-analysis has 
been published on PROSPERO (ID: CRD42020179002).
Data sources and search strategy
A search of current literature was carried out in 4 databases: 
MEDLINE (1946 to March week 3 2020), EMBASE (1974 to 
31 March 2020), CINAHL Plus (1937 to March week 3 2020), 
and PsycINFO (1806 to March week 3 2020). The search strategy 
was: (Coronavirus OR Coronavirus Infections OR SARS virus 
OR Severe acute respiratory syndrome OR MERS OR Middle 
east respiratory syndrome OR COVID) AND (Follow-up OR 
Follow-up studies OR Prevalence). Terms were entered as MeSH 
terms, where available, for each database, otherwise these were 
searched as keywords in the title, abstract, and subject headings.
Inclusion and exclusion criteria
Population. Clinical studies involving adults with a confirmed 
diagnosis of SARS or MERS were included. 
Exposure. Studies reporting patients with SARS or MERS 
were included.
Study Studies had to follow up patients for a minimum of 3 
months post-admission or 2 months post-discharge to be inclu-
ded in this review. Only primary research studies were included. 
Reviews, case-reports, and editorial reports were excluded.
Outcomes. Studies were required to monitor changes in clinical 
symptoms at follow-up in order to be included. Studies that 
only monitored changes in serological or immunological results 
without any assessment of clinical status of the patient were 
excluded. Likewise, studies reporting only radiological appea-
rance of lung disease or osteonecrosis without any mention of 
any clinical outcomes were excluded.
Selection process
All studies were first screened using the title and abstract. At this 
stage abstracts with any mention of follow-up were included 
to avoid exclusion of abstracts that did not report the length of 
follow-up. Similarly, abstracts that reported follow-up for any 
outcome were accepted in order to allow inclusion of studies 
in which clinical findings were not significant and therefore not 
reported in the abstract. Full texts of selected abstracts were then 
screened to ensure that all of the above selection criteria were met. 
The final included studies were then critically appraised and 
graded. Screening and grading were undertaken by 4 indepen-
dent reviewers (KP, HA, MS, and SH). Author DG was involved 
in cases of disagreement
Data extraction
Data were extracted into standardized tables for each medical 
system. The following data were extracted: study, year, coun-
try, type of coronavirus outbreak, sample size, follow-up rate, 
age, sex, settings (hospital/ICU admission), follow-up period, 
prevalence of key outcomes, and mean score for assessment of 
each outcome. Where estimates were only provided separately 
for 2 or more subgroups, the weighted average across those 
subgroups was taken as the estimate for the overall population. 
Extraction was performed by at least 2 independent authors and 
further cross-checked by 2 other authors.
Quality assessment
Studies were graded using the Oxford Centre for Evidence-
Based Medicine (OCEBM) 2009 Level of Evidence Tool (Table 
SI) (6). The initial level of evidence was assigned depending 
on the type of study. Prospective cohort studies were then 
downgraded if the follow-up rate was < 80%. 
Data analysis
Binary data for prevalence of outcomes were pooled using meta-
analysis by mixed-effects logistic regression, directly modelling 
the number of subjects with impaired function using a binomial 
distribution. Mean scores for different outcomes were pooled in 
a meta-analysis using random effects models (7). Forest plots 
were stratified by duration of follow-up (up to 6 months and 
over 6 months). Where a study presented more than one result 
within a subgroup, the value closest to 6 months (for up to 6 
months) or to closest to 12 months (for over 6 months) was 
selected. Between-study heterogeneity was assessed as the 
range of study estimates and the proportion of total variability 
attributable to between-study heterogeneity (8). There were too 
few studies to formally explore the sources of heterogeneity 
through meta-regression (e.g. by mean age, disease, % male, or 
level of evidence) or to examine potential small-study effects, 
such as publication bias through funnel plots. All statistical 
analyses were conducted using Stata version 15 (9).
Role of the funding source
There was no funding source for this study.
RESULTS
A total of 1,169 studies were identified from the 
databases. Of these, 104 abstracts were selected for 
full-text screening and a final total of 28 studies were 
included in the systematic review and 23 included 
in the meta-analysis. The reasons for exclusion are 
reported in Fig. 1. 
Out of the 28 studies included in this review, 26 re-
ported findings from the SARS outbreak and 2 reported 
findings from the MERS outbreak. The cohorts studied 
were from Beijing (11 studies), Hong Kong (9 studies), 
Guangzhou (1 study), Singapore (2 studies), Taiwan 
(2 studies), Korea (2 studies), and Canada (1 study), 
which were the regions that were severely affected by 
the previous outbreaks. The sample size ranged from 
a case series of 4 patients to a cohort study of 406 
patients. Based on OCEBM grading, 15 studies were 
graded Level 1b, 8 Level 2b, 2 Level 3b, and 3 Level 4. 
www.medicaljournals.se/jrm
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The 28 studies in the review reported outcomes 
involving multiple organ systems.The studies mainly 
addressed one or more of 5 key outcomes of interest: 
lung function (18 studies), mental health (6 studies), 
exercise tolerance (5 studies), health-related quality of 
life (HRQoL) (5 studies), ocular outcomes (1 study), 
and neuromuscular outcomes (1 study). The study cha-
racterstics and results for each key outcome of interest 
are presented in Tables I–V. Additional data for lung 
function, mental health, and quality of life are shown 
in Tables SII–SIV.
A total of 18 studies (9 Level 1b, 4 Level 2b, 3 Level 
3b, and 2 Level 4 studies) reported lung function out-
comes in CoV survivors, of which 16 were included in 
the meta-analysis. Chen et al. (11) only reported changes 
in symptoms without any report of lung function para-
meters which could be included in this meta-analysis. 
Zheng-Yu et al. (14) did not report standard deviations, 
hence the data could not be used in the meta-analysis. 
All studies defined an abnormality in each lung function 
parameter as a value of < 80% of the predicted value. 
Studies reporting prevalence of abnormality in diffusing 
capacity of the lung for carbon monoxide (DLCO) (10 
studies), forced expiratory volume in 1 s (FEV1) (6 
studies), forced vital capacity (FVC) (5 studies), and 
total lung capacity (TLC) (4 studies) were used to ob-
tain pooled prevalence of each abnormality (Fig. 2 and 
Fig. S11). At 6 months post-discharge, abnormalities in 
DLCO, FVC, and TLC were more prevalent than abnor-
malities in FEV1. Most of these abnormalities improved 
after 6 months after discharge; however, the prevalence 
of DLCO impairment remained considerably high even 
6 months beyond discharge, with a pooled estimate of 
24.35 (95% confidence interval (95% CI) 11.05–45.46). 
Studies reporting mean values for DLCO (10 studies), 
FEV1 (10 studies), FVC (10 studies), FEV1/FVC (6 stu-
dies), vital capacity (VC) (4 studies), diffusing capacity 
of the lung for carbon monoxide: alveolar ventilation 
(DLCO:Va) (3 studies), and TLC (8 studies) were used 
to pool mean values for each abnormality up to and 
beyond 6 months after discharge (Fig. S21). None of the 
pooled estimates for the mean values of these parameters 
were <80% of predicted. 
Five studies (4 Level 1b studies and one Level 2b 
study) reported exercise tolerance outcomes in CoV 
survivors, of which 4 were included in this meta-
analysis (Fig. S31). Results from Ong et al.’s study (27) 
1http://www.medicaljournals.se/jrm/content/?doi=10.2340/16501977-2694
Fig. 1. PRISMA Flowchart for the Literature Search.
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EMBASE
(n=912)
MEDLINE
(n=430)
PsycINFO
(n=33)
CINAHL Plus
(n=244)
Records after duplicates Removed
(n=1,169)
Records Screened
(n=1,169)
Full-text articles assessed
(n=104)
Studies Included in Review
(n=28)
Records Excluded based on Full-Text (n=76)
• Follow-up period less than 2 months post-discharge or 3 months 
post-admission (n=10)
• No clinical outcome followed-up (n=53)
• Non SARS/MERS case (n=6)
• Results presented in another paper (n=7)
Records Excluded based on Abstracts (n=1,065)
• Participants not adults (n=380)
• Non-original research and reviews (n=257)
• Case-reports (n=45)
• No diagnosis of coronavirus (n=171)
• No follow-up post infection (n=201)
• No abstract available (n=11)
Duplicates Removed (n=450)
Studies Included in Meta-Analysis
(n=23)
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Table I.  Lung function outcomes in coronavirus survivors
Patient demographics Prevalence of lung function abnormalities
Study, 
(Year)
Coronavirus 
outbreak Country
Level of 
evidence
Sample 
size, n Setting
Follow-up 
period
PA or 
PD
Patients 
followed-up, 
% (n/total)
Prevalence 
of ↓DLCO, 
% (n/total)
Prevalence 
of ↓FEV1, % 
(n/total)
Prevalence of 
↓FVC, % (n/
total)
Prevalence 
of abnormal 
TLC, % (n/
total) Notes
He et al. 
(2005) 
(10)
SARS Beijing 1b 406 Hospital 6 months PD 99 (404/406) 41 
(165/404)
1 (3/406) .. .. ..
Chen et 
al. (2006) 
(11)
SARS Beijing 1b 124 Hospital 3 months PD 89 (111/124) .. .. .. .. **
18 months PD 89 (111/124) .. .. .. .. **
Tansey et al. 
(2007) (12)
SARS Toronto 1b 117 Hospital 3 months PD 100 (84/84) .. .. .. .. **
      6 months PD 100 (100/100) .. .. .. .. **
      12 months PD 100 (117/117) .. .. .. .. **
Hui et al. 
(2005) 
(13)
SARS Hong Kong 1b 110 Hospital 
and 
ICU
3 months PA 88 (97/110) 13.5 
(13/97)
3 (3/97) 6 (6/97) 7 (7/97) ..
6 months PA 88 (97/110) 16 (15/97) 4 (4/97) 4 (4/97) 8 (8/97) ..
12 months PA 88 (97/110) 24 (23/97) 5 (5/97) 4 (4/97) 5 (5/97) ..
Zheng-
Yu et al. 
(2003) 
(14)
SARS Beijing 1b 100 Hospital 2 months PD 91 (91/100) .. .. .. .. **
Ong et al. 
(2005) 
(15)
SARS Singapore 1b   94 Hospital 
and 
ICU
12 months PD 100 (94/94) 21.3 
(20/94)
21.3 (20/94) 12.8 (12/94) 8.5 (8/94) **
Park et al. 
(2018) (5)
MERS Korea 1b   73 Nation-
wide
12 months PD 100 (73/73) 34 (25/73) 8 (6/73) 8 (6/73) .. ..
Li et al. 
(2006) 
(16)
SARS Hong Kong 1b   45 ICU 3 months PA 80 (36/45) .. .. .. .. **
6 months PA 80 (36/45) .. .. .. .. **
12 months PA 80 (36/45) .. .. .. .. **
Liu et al. 
(2007) (17)
SARS Beijing 1b   37 Hospital 1 month PD 100 (37/37) 32.4 
(12/37)
24.3 (9/37) 27 (12/37) .. ..
      3 months PD 100 (37/37) 16.2 (6/37) 29.7 (11/37) 32.4 (12/37) .. ..
      12 months PD 100 (37/37) 10.8 (4/37) 32.4 (12/37) 29.75 (11/37) .. ..
      3 years. PD 100 (37/37) 5.4 (2/37) 32.4 (12/37) 32.4 (12/37) .. ..
Ng et al.
(2004) (18)
SARS Hong Kong 2b   93 Hospital 6 months PA 59 (57/97) 35 (20/57) 16 (9/57) 7 (4/57) 30 (17/57) ..
Zheng et al. 
(2005) (19) 
SARS Guangzhou 
(China)
2b   80 Hospital 6 months PD 33 (26/80) 65 (17/26) .. .. .. **
      9 months PD   33 (26/80) .. .. .. .. **
      9–12 months PD   33 (26/80) .. .. .. .. **
      12–15 months PD   33 (26/80) .. .. .. .. **
      15–18 months PD   33 (26/80) .. .. .. .. **
Zhang et al. 
(2020) (20) 
SARS Beijing 2b   71 Hospital 2 years. PD   65 (46/71) 35 (16/46) .. .. 22 (10/46) ..
15 years. PD   73 (52/71) 38 (18/52) .. .. 0 (0/52) ..
Chiang et al. 
(2004) (21)
SARS Taiwan 2b   14 Hospital 6 months PA   64 (9/14) 50 (5/9) .. .. .. ..
Xie et al. 
(2005) (22) 
SARS Beijing 3b 311 Hospital 2 months PD   13 (40/311) .. .. .. .. **
4 months PD   13 (40/311) .. .. .. .. **
6 months PD   13 (40/311) .. .. .. .. **
11 months PD   13 (40/311) .. .. .. .. **
Guo-xin et 
al. (2005) 
(23)
SARS Beijing 3b 181 Hospital 6 months PD 100 (181/181) 25 (46/181) .. .. .. ..
Wong et al. 
(2004) (24)
SARS Hong Kong 3b   99 Hospital 3 months PA 54 (53/99) .. .. .. .. **
6 months PA 37 (37/99) .. .. .. .. **
Yin et al. 
(2005) (25)
SARS Beijing 4 .. Hospital 1 month PD 20 5 (1/20) 15 (3/20) .. .. ..
     3 months PD 21 0 (0/20) 5 (1/20) .. .. ..
     6 months PD 22 0 (0/20) 5 (1/20) .. .. ..
      12 months PD 23 0 (0/20) 0 (0/20) .. .. ..
Wu et al. 
(2016) (26) 
SARS Beijing 4 .. Hospital 7 years PD 11 82 (9/11) .. .. .. **
DLCO: Diffusing capacity for carbon monoxide; FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; TLC: Total Lung Capacity; SARS: Severe 
acute respiratory syndrome; MERS: Middle East respiratory syndrome; PA/D: post-admission/discharge; **: Mean scores for lung function parameters or prevalence 
of respiratory syndromes provided in the supplementary tables for these studies.
www.medicaljournals.se/jrm
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Table II. Exercise tolerance outcomes in coronavirus survivors
Patient Demographics Exercise Outcomes
Study 
(Year)
Coronavirus 
outbreak Country Level
Sample 
size, n
Age 
Mean (SD)
Sex, % 
male, (n/
total) Setting
Follow-up 
period
PA or 
PD
Patients 
followed-up, 
% (n/total)
Exercise 
test
Prevalence, 
% (n/total) 
of reduced 
VO2max
6MWD, m
Mean (SD)
Hui et al. 
(2005) (13) 
SARS Hong Kong 1b 110 37 (10) 40 (39/97) Hospital 
and ICU
3 months PA 88 (97/110) 6MWD .. 464 (87)*
        6 months PA 88 (97/110) 6MWD .. 502 (97)*a
        12 months PA 88 (97/110) 6MWD .. 511 (90)*a
Park et al. 
(2018) (5)
MERS Republic/
Korea
1b 73 51 (13) 60 (43/73) Hospital 12 months PD 100 (73/73) 6MWD .. 540 (172)
Ong et al. 
(2004) (27)
SARS Singapore 1b 46 37 (11) 26 (12/44) Hospital 
and ICU
3 months PD 96 (44/46) CPET 41 (18/44) ..
Li et al. 
(2006) (16)
SARS Hong Kong 1b 36 42 (12) 54 (24/80) ICU 3 months PA 100 (36/36) 6MWD .. 454 (98)
6 months PA 100 (36/36) 6MWD ..
12 months PA 100 (36/36) 6MWD .. 506 (111)
Lam et al. 
(2006) (28)
SARS Hong Kong 2b 116 46 (15) 44 (51/81) Hospital 2 months PA 70 (81/116) 6MWD .. 468 (111)
        8 months PA 70 (81/116) 6MWD .. 577 (96)
6MWD:  6-minute walking distance; CPET: Cardiopulmonary exercise test; VO2max: Maximal oxygen uptake; SARS: Severe acute respiratory syndrome; MERS 
Middle East respiratory syndrome; PA: post admission; PD: post discharge (*significantly less than controls; asignificantly; > 3 months)
Table III. Mental health outcomes in coronavirus survivors
Patient demographics Prevalence of mental health outcomes
Study 
(Year)
Coronavirus 
outbreak Country
Level of 
evidence
Sample 
size, n
Age, 
Mean 
(SD)
Sex, % 
male 
(n/total) Setting
Follow-up 
period
PA or 
PD
Patients 
followed-
up, % (n/
total)
Prevalence 
of PTSD, 
% (n/
total)
Prevalence 
of 
Depression, 
% (n/total)
Prevalence 
of anxiety, 
% (n/
total)
Prevalence 
of chronic 
fatigue, % 
(n/total)
Prevalence 
of pain 
Disorder, 
% (n) Notes
Lee 
et al. 
(2007) 
(29)
SARS Hong 
Kong
1b 120 .. 36 
(35/96)
Hospital 12 
months
PD 80 
(96/120)
32.2 
(25/79)
40.7 
(32/79)
51.5 
(41/79)
.. .. **
          (IES-R) (DASS) (DASS) .. ..
Mak 
et al. 
(2009) 
(30)
SARS Hong 
Kong
1b   93 41 
(12)
38 
(34/90)
Hospital 2.5 years PA 96.8 
(90/93)
25.6 
(23/90)
15.6 
(14/90)
15.2 
(13/90)
.. ..
(IES-R) (HADS) (HADS) .. ..
Gao 
et al. 
(2006) 
(31)
SARS Beijing 1b   76 25 
(9)
31 
(21/67)
Hospital 3 months PD 88 
(67/76)
46.2 
(31/67)
.. .. .. ..
       12 
months
PD 88 
(67/76)
38.8 
(26/67)
.. .. .. ..
           (PTSD-SS) .. .. .. ..
Hong 
et al. 
(2009) 
(32)
SARS Beijing 1b   70 39 
(12)
33 
(23/70)
Hospital 2 months PD 100 
(70/70)
40.0 
(28/70)
.. .. .. ..
7 months 86 
(60/70)
41.0 
(25/60)
.. .. .. .. **
10 
months
81 
(57/70)
38.6 
(22/57)
.. .. .. ..
20 
months
83 
(58/70)
39.7 
(23/58)
.. .. .. ..
4 years 83 
(57/70)
42.1 
(24/58)
.. .. .. ..
(CCMD-
III)
.. .. .. ..
Lee 
et al. 
(2019) 
(33)
MERS Korea 1b   72 50 
(12)
62 
(32/52)
Hospital 12 
months
PD 88 
(63/72)
42.3 
(27/63)
26.9 
(17/63)
.. 48.1 
(30/63)
..
        18 
months
.. 75 
(54/72)
26.9 
(15/54)
17.3 (9/54) .. 32.7 
(18/54)
.. **
           (IES-R) (PHQ-9) .. (FSS) ..
Lam 
et al. 
(2009) 
(34)
SARS Hong 
Kong
2b 233 43 
(14)
30 
(69/233)
Hospital 3.5 years PD 78 
(181/233)
54.5 
(127/233)
39 
(91/233)
.. 40.3 
(94/233)
36.4 **
(IES-R) (HADS) .. (CFQ) (85/233)
PTSD: Post-traumatic stress disorder; DASS: Depression and Anxiety Stress Scale; IES-R: Impact of Events- Revised; HADS: Hospital Anxiety and Depression Scale; 
PTSD-SS: PTSD self-rating scale; CCMD-III: Chinese classification of mental disorders; CFQ: Chalder Fatigue Questionnaire; PHQ: Patient Health Questionnaire; 
FSS: Fatigue Severity Scale; CDC: Centres for Disease Control; SARS: Severe acute respiratory syndrome; MERS: Middle east respiratory syndrome; PA/D: post-
admission/discharge; ** Mean scores for different psychological condition assessment provided in the supplementary material.
J Rehabil Med 52, 2020
JR
M
JR
M
Jo
ur
na
l o
f 
R
eh
ab
ili
ta
ti
on
 M
ed
ic
in
e
JR
M
Jo
ur
na
l o
f 
R
eh
ab
ili
ta
ti
on
 M
ed
ic
in
e
H. Ahmed et al.p. 6 of 11
were not included because they only reported outcomes 
from cardiopulmonary exercise testing (CPET) and 
did not conduct 6-min walking distance (6MWD) 
tests. The pooled estimate of 6MWD for 3 studies re-
porting outcomes up to 6 months was 461.18 (95% CI 
449.66–472.71). The 6MWD increased substantially 
after 6 months, with pooled estimate of 533.00 (95% 
CI 449.66–472.71). Since ~30 m is considered to be 
the minimal clinically important difference in 6MWD 
(37), patients seem to improve significantly over time. 
Unfortunately, data were not available regarding the 
6MWD for participants before CoV infection, and 
therefore there is no report of the number of patients 
with exercise tolerance lower than baseline.
Six studies (5 Level 1b and one Level 2b study) re-
ported psychological comorbidities in CoV survivors, 
of which all 6 were included in the meta-analysis. All 
studies that reported prevalence of these psychologi-
Table V. Miscellaneous outcomes in coronavirus survivors
Study 
(Year)
Coronavirus 
outbreak System Country Level
Sample 
Size, n
Age, 
Mean (SD)
Sex, male
% (n/total) Setting
Follow-up 
period
Post-
admission 
(PA) or 
Post-
discharge 
(PD)
Patients 
followed-
up, % (n/
total) Notes
Yuen et 
al. (2004) 
(35)
SARS Ophthal-
mic
Hong Kong 2b 45 39 (13) 38 (17/45) Hospital 3 mon PD 33 (15/45) Elevated intraocular 
pressure: 2 patients 
(baseline), 2 patients 
(2 months), 1 patient 
(3 months)
No ocular manifestations 
of coronavirus were 
observed
Tsai et al. 
(2004) 
(36)
SARS Neuro-
muscular
Taiwan 4   4 46 (7) 25 (1 / 4) ICU 3 mon PA 100 (4/4) Series of patients 
developed distal-
predominant weakness 
of 4 limbs, mild 
hyporeflexia and 
hypesthesia in legs on 
day 21, 22, 24 and 
25 with recovery of 
muscle power in all 
patients at 3 months 
follow-up
SARS; severe acute respiratory syndrome; MERS; Middle East Respiratory syndrome; PA: post admission; PD: post discharge.
Table IV. Quality of life outcomes in coronavirus survivors 
Patient Demographics SF-36 DOMAIN SCORES 
Study 
(Year)
Corona-
virus 
outbreak Country Level
Sample 
size, n
Age, 
Mean 
(SD)
Sex,  
male  
% (n/
total) Setting
Follow-up 
Period
PA 
or 
PD
Patients 
followed-up, 
% (n/total)
Physical 
functioning, 
Mean (SD)
Role 
limitations 
(Physical), 
Mean SD)
Body 
pain 
Mean 
(SD)
General 
health 
Mean 
(SD)
Vitality 
Mean 
(SD)
Social 
functioning 
Mean (SD)
Mental 
health 
Mean 
(SD)
Role 
limitation 
(Emotional) 
Mean (SD) Notes
Tansey 
et al. 
(2007) 
(12)
SARS Toronto 1b 117 42 
(13)
33 
(39/117)
Hospital 3 months PD 72 (84/117) 35.8 42 45.2 42.2 38.8 35.4 43.2 40.2 **
        6 months PD 85 
(100/117)
42 45.6 46.6 42.2 41.6 41 46 43.2
        12 
months
PD 100 
(117/117)
41 45.4 47 42.8 42.8 42 47.8 43.2
Hui 
et al. 
(2005) 
(13)
SARS Hong Kong 1b 110 37 
(10)
40 
(39/97)
Hospital 3 months PA 88 (97/110) 77.8 (31.4) 38.8 
(76.2)
69.6 
(49.8)
48.6 
(21.2)
42.9 
(18.1)
57.0 (48.3) 59.0 
(32.1)
48.7 (75.5)
        6 months PA 88 (97/110) 79.6 (36.1) 61.7 
(80.7)
68.0 
(50.3)
47.5 
(32.4)
43.9 
(19.8)
65.0 (39.3) 60.1 
(29.7)
64.1 (67.4)
        12 
months
PA 88 (97/110) 78.8 (39.6) 59.0 
(81.1)
65.1 
(49.9)
45.2 
(33.4)
41.9 
(22.6)
62.1 (26.4) 60.6 
(33.5)
61.8 (76.9)
Ong 
et al. 
(2005) 
(15)
SARS Singapore 1b   94 37 
(12)
26 
(24/94)
Hospital 12 
months
PD 100 (94/94) .. ..  .. .. ..  .. .. .. **
Hong 
et al. 
(2009) 
(32)
SARS Beijing 1b   70 39 
(12)
33 
(23/70)
Hospital 10 
months
PD 81 (57/70) 73.7 (30.9) 58.3 
(44.6)
64.5 
(28.0)
51.5 
(28.9)
58.5 
(26.9)
68.8 (31.2) 70.0 
(21.4)
67.6 (42.9)
Lam 
et al. 
(2006) 
(28)
SARS Hong 
Kong
2b 116 46 
(15)
44 
(51/81)
Hospital 6 mon PA 70 (81/116) 69.9 (23.3) 32.7 
(40.5)
53.2 
(26.1)
40.4 
(23.6)
50.7 
(20.5)
65.5 (28.0) 64.7 
(21.4)
37.5 (40.3) **
SF-36: Short form 36 health survey; SARS: Severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; PA/D: post-admission/discharge; **: 
St George’s Respiratory Questionnaire (SGRQ) data presented in Table S4.
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Fig. 2. Summary Forest plot showing pooled estimate of prevalence of different lung function abnormalities in CoV survivors up to 6 months (top) 
and over 6 months (bottom).
Fig. 3. Summary Forest plot showing pooled estimate of prevalence of different psychological conditions in CoV survivors over 6 months
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There seems to be some improvement in these domains 
beyond 6 months, but the scores were still lower than 
healthy and chronic disease patients (38). 
Other outcomes that have been followed-up in SARS 
patients are reported in Table V. A 2004 study by Yuen et 
al. (35) found no eye pathologies in this cohort. A 2004 
case series study by Tsai et al. (36) followed up patients 
who developed limb weakness related to critical illness 
neuropathy (CIN) and myopathy (CIM) and sensory de-
ficits following infection. All these patients had partial or 
full recovery of muscle power 3 months after admission.
DISCUSSION
This systematic review collates the long-term (> 3 
month) complications following SARS and MERS 
in patients who required hospitalization or ICU stay. 
HRQoL, measured using SF-36, was considerably 
reduced in survivors at 6 months post-infection, and 
showed only slight improvement beyond 6 months. 
HRQoL of survivors remained below that of the normal 
population and of those with chronic conditions (Fig. 
4). Since these SF-36 scores reflect impairment in 
physical, mental, and social functioning of well-being, 
it is not surprising that the key areas of impairments 
identified in our systematic review were pulmonary 
cal conditions had follow-up periods longer than 6 
months. As a result, meta-analysis was conducted for 
prevalence beyond 6 months post-discharge only. The 
prevalence of different psychological conditions was 
substantially high, with pooled estimates of 38.80% 
(95% CI 30.93–47.31) for post-traumatic stress disorder 
(PTSD), 33.20% (95% CI 19.80–50.05) for depression, 
and 30.04% (95% CI 10.44–61.26) for anxiety (Fig. 
3 and Fig. S41). It was not possible to perform meta-
analysis on the mean scores for different psychological 
comorbidities because different scales were used to 
report these in different studies.
Five studies (4 Level 1b studies and one Level 2b 
study) reported quality of life outcomes in CoV sur-
vivors. Of these, only 3 studies, which reported both 
mean and SD, were included in the meta-analysis of 
Short Form 36 health survey (SF-36) (Fig. S51) and St 
George’s Respiratory Questionnaire (SGRQ) (Fig. S61) 
each. Pooled analysis showed that the mean score for 
all of the 8 domains of the SF-36 were substantially 
lower in CoV survivors than normative values for pe-
ople who are healthy, as well as for people with chronic 
diseases derived from existing validated literature (38) 
(Fig. 4). Domains that scored particularly lower than 
healthy individuals and those chronic conditions were 
role limitations due to physical and emotional health. 
Fig. 4. Radar plot showing pooled estimate of mean scores for different domains of SF-36 in coronavirus survivors up to 6 months (green) and 
over 6 months (orange) compared to healthy individuals (blue) and subjects with chronic conditions (red).
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dysfunction, reduced exercise tolerance, and psycho-
logical problems.
Respiratory compromise is one of the key physical 
issues in survivors of SARS and MERS. The impair-
ment is mainly restrictive in nature, with predominance 
of abnormalities in DLCO, VC, and TLC, compared 
with FEV1, thereby supporting the aetiopathology of 
ARDS with parenchymal infiltration caused by the 
infection. Even though lung function improves over 
time, the results of the current meta-analysis showed 
that reduction in DLCO may still be present in 11–45% 
of CoV survivors at 12 months. This is consistent with 
CT findings from other studies, which have reported 
that pulmonary fibrosis can persist for up to 7 years 
(26). Considering that pulmonary rehabilitation has 
shown positive results in patients with fibrosis, such 
intervention, if employed at an early stage, has the 
potential to improve outcomes long-term (39).
SARS survivors had reduced aerobic capacity, with 
peak oxygen uptake (VO2max) testing showing impair-
ments in 41% of patients at 3 months (27). This could 
be due to circulatory limitation, muscle weakness, 
critical illness neuropathy and myopathy (CINM), 
and deconditioning (27). The 6MWD is also reduced 
in SARS and MERS survivors at 3 months and slowly 
improves by 12 months (13, 16). Such chronic weak-
ness may be present in patients even 5 years after ICU 
admission; therefore, the rehabilitation needs of these 
patients can be prolonged (40). Early rehabilitation 
combining mobilization with strengthening exercises 
may improve exercise tolerance in these patient groups, 
as there is substantial evidence for improvement in 
weakness and functional independence in CINM (41).
The current meta-analysis showed that approxima-
tely one-third of SARS and MERS survivors may have 
psychological conditions, such as PTSD, depression, 
and anxiety beyond 6 months. These estimates are 
much higher than the prevalence of these conditions 
reported as part of post-ICU syndrome in medical and 
surgical patients (42). This indicates that the long-
lasting mental health impact is not from serious illness 
alone, but also from factors such as fear (43), stigma 
(34) and difficulties and compliance with quarantine 
(44), and the psychological impact of the quarantine 
experience.
SF-36 scores for role limitations in SARS survivors 
were particularly low compared with healthy indivi-
duals. A 2007 study by Tansey et al. (12) reported that 
17% of SARS survivors had not returned to their pre-
vious level of working even at one year post-infection. 
Many of the symptoms experienced by SARS survivors 
could be responsible for such reduced social functio-
ning. Fatigue was reported in at least one-third of the 
patients in 2 studies, with a follow-up period of 18 
months (33) and 40 months (34), respectively. Pain di-
sorders were followed up in one study, which reported 
that these were present in approximately one-third of 
patients around 3.5 years after SARS infection (34).
Differences in outcomes between ICU and non-
ICU patients remain unclear. Whilst one study iden-
tified that lung function parameters, such as FVC 
and DLCO, were comparatively lower in the ICU 
group (13), another reported no significant difference 
between the 2 groups (27). It is known that muscle 
weakness developed during ICU admission has been 
associated with substantial impairments in physical 
function and quality of life following acute lung 
injury (45), and therefore it could be hypothesised 
that SARS and MERS ICU survivors may have suf-
fered worse outcomes. 
The main strength of this study is that it highlights 
multiple long-term biopsychosocial impairments 
which may hinder return to pre-infection functional 
status. This is the first systematic review and meta-
analysis on this topic as far as we are aware. Unlike 
a previous review from 2003 (4), we investigated 
long-term outcomes from major SARS and MERS 
outbreaks this century. We have tried to capture the 
various aspects of well-being and health-related quality 
of life in CoV survivors. 
A weakness of our review was the large between 
study heterogeneity of studies included - almost all 
I-squared estimates >50%. and a wide range of re-
sults observed across studies. Pooled estimates must 
therefore be interpreted cautiously, particularly when 
comparing the data up to 6 months with the results 
over 6 months. We were unable to formally explore 
sources of this heterogeneity because of the small num-
bers, but these could include study-level differences 
in mean ages, gender, differences between SARS and 
MERS outbreaks, referral pathways between regions, 
and study design. 
At this stage it is not possible to conclude whether 
the long-term outcomes identified in SARS and MERS 
patients will also occur in COVID-19 survivors. Howe-
ver, as SARS and MERS belong to the same family of 
virus as COVID-19, and the clinical features are similar 
(1, 3), as well as providing a critical assessment of the 
risk factors and actionable items for stopping their 
spread, based on the lessons learned from the first 2 
deadly coronavirus outbreaks, as well as results from 
initial reports on the current COVID-19 coronavirus 
pandemic, clinicians should anticipate a similar range 
of long-term outcomes in survivors of COVID-19 
following hospitalization and ICU admission. Further 
studies should therefore be performed in these patients 
in order to follow up lung function abnormalities, re-
duced exercise capacity, psychological impairments, 
and reduced quality of life, as identified in SARS 
and MERS patients. Practical approaches are recom-
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mended early in the COVID-19 outbreak to mitigate 
against the potential long-term outcomes identified in 
the current review. Acute multidisciplinary rehabilita-
tion during hospital stay, post-acute rehabilitation in 
step-down rehabilitation or respiratory units and long-
term rehabilitation interventions are recommended to 
optimize physical, psychological and functional reco-
very in these individuals. In summary, it is clear from 
the SARS and MERS epidemics that clinicians should 
monitor the survivors of COVID-19 for the range of 
physical and mental health impairments identified in 
this review, in order to manage them appropriately.
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